Items tagged “theranostics”

Prostate-specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II, is a type II transmembrane glycoprotein that has become an increasingly prominent imaging biomarker 1. PSMA has emerged as a useful target in PET imaging of prostate cancer, especially in the evaluation of sm...

Yttrium-90 (90Y) is a radioisotope derived from the decay of 90Sr. Yttrium-90 decays due to the emission of β- particles, with a half-life of 2.67 days 5. It has no gamma energy emission, but may be imaged through the use of bremsstrahlung interactions with planar or SPECT imaging. A small amou...

Theranostics, also known as  theragnostics 6, uses a diagnostic examination to determine if a patient may benefit from a specific therapeutic drug and thus couples the therapy with diagnostic information specific for the intended target 2. Theranostics promises improved patient selection for th...

PSMA theranostics is an emerging nuclear medicine approach in the management of prostate cancer that combines the use of prostate-specific membrane antigen (PSMA)-targeted imaging and therapy 1. PSMA-targeted imaging can be used to identify and locate prostate cancer cells, while PSMA radioligan...

Iodine-131 iobenguane, trade name Azedra, sometimes referred to as I-131 MIBG, is a theranostic (i.e. both therapeutic and diagnostic) agent used for the treatment of unresectable pheochromocytomas, paragangliomas, carcinoid, and neuroblastomas.   It is created using the high specificity Ultratr...

Lutetium-177 dotatate, also known as Lu-177 oxodotreotide and by the trade name Lutathera (Novartis Pharmaceuticals Corporation, USA), is a theranostic agent approved as a second-line agent for the treatment of patients with inoperable and/or metastatic well-differentiated neuroendocrine tumors ...

Lutetium-177 vipivotide tetraxetan, trade name Pluvicto, also known as 177Lu-PSMA-617, is a theranostic (i.e. both therapeutic and diagnostic) agent approved as a treatment for adult patients with treatment-resistant advanced metastatic prostate cancer.  The treatment works by binding to cancer ...

Radium-223 dichloride, trade name Xofigo, is a radiopharmaceutical approved for the treatment of patients with symptomatic bone metastases and no visceral disease from prostate cancer resistant to anti androgen therapy. The molecule mimics calcium and forms a complex with hydroxyapatite at sites...

Yttrium-90 ibritumomab tiuxetan, also known by the trade name Zevalin (Acrotech Biopharma LLC, USA), is a theranostic radiopharmaceutical approved for the treatment of patients with relapsed or refractory low grade or follicular non-Hodgkin lymphoma (NHL). More specifically, it is a radioimmunot...